May 29, 2024 8:30am EDT Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
May 13, 2024 8:00am EDT Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 10, 2024 9:00am EDT Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
Apr 23, 2024 8:30am EDT Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
Apr 22, 2024 8:30am EDT Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
Mar 25, 2024 8:00am EDT Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
Mar 12, 2024 9:15am EDT Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
Feb 15, 2024 9:00am EST Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th
Jan 23, 2024 8:30am EST Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
Jan 08, 2024 8:30am EST Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
